Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).
2016 ◽
Vol 34
(15_suppl)
◽
pp. TPS2596-TPS2596
◽
Keyword(s):
Phase Ii
◽